With regard to Public Health Agency of Canada (PHAC), the Ad-hoc COVID-19 Clinical Pharmacology Task Group and Health Canada (HC) research or communication about lvermectin: (a) did they find any harm to Canadians from taking oral lvermectin to prevent or treat COVID-19; (b) did HC, PHAC, or a committee review the lvermectin meta-analysis conducted by Andrew Bryant, lvermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines, American Journal of Therapeutics, 28, e434-e460, July 2021, (i) did their analysis show any benefit from using lvermectin to prevent or treat COVID-19; (c) did HC or PHAC perform a risk-harm analysis for the use of lvermectin to prevent or treat COVID-19, (i) if the answer to (c) is negative, why not, (ii) if the answer to (c) is affirmative, was this information provided to Dr. Theresa Tam, Dr. Supryia Sharma, or the Minister of Health, (iii) what dates was the information from (ii) communicated, (iv) if the answer to (ii) is negative, why not?
In the House of Commons on January 29th, 2024. See this statement in context.